1. Signaling Pathways
  2. Epigenetics
    JAK/STAT Signaling
    Protein Tyrosine Kinase/RTK
    Stem Cell/Wnt
  3. JAK
  4. JAK Inhibitors

JAK Inhibitors

JAK1

JAK2

JAK3

Tyk2

JAK

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

JAK Inhibitors, Activators & Modulators
Product Name JAK1 JAK2 JAK3 Tyk2 JAK Purity
Ruxolitinib
JAK1, IC50: 3.3 nM
JAK2, IC50: 2.8 nM
JAK3, IC50: 428 nM
Tyk2, IC50: 19 nM
  99.99%
Tofacitinib
JAK1, IC50: 112 nM
JAK2, IC50: 20 nM
JAK3, IC50: 1 nM
    99.99%
Baricitinib
JAK1, IC50: 5.9 nM
JAK2, IC50: 5.7 nM
JAK3, IC50: 560 nM
Tyk2, IC50: 53 nM
  99.70%
Deucravacitinib
JAK1 JH2, IC50: 1 nM
   
Tyk2 JH2, IC50: 0.2 nM
  99.79%
VVD-118313
JAK1
       
BI-1622    
JAK3
    98.97%
Upadacitinib
JAK1, IC50: 0.043 μM
JAK2, IC50: 0.2 μM
JAK3, IC50: 2.3 μM
Tyk2, IC50: 4.7 μM
  99.96%
Fedratinib  
JAK2, IC50: 3 nM
JAK2(V617F), IC50: 3 nM
      99.87%
Ruxolitinib phosphate
JAK1, IC50: 3.3 nM
JAK2, IC50: 2.8 nM
JAK3, IC50: 428 nM
Tyk2, IC50: 19 nM
  99.98%
Tofacitinib citrate
JAK1, IC50: 112 nM
JAK2, IC50: 20 nM
JAK3, IC50: 1 nM
    99.98%
Pacritinib
JAK1, IC50: 1280 nM
JAK2V617F, IC50: 19 nM
JAK2wt, IC50: 23 nM
JAK3, IC50: 520 nM
Tyk2, IC50: 50 nM
  99.93%
Momelotinib
JAK1, IC50: 11 nM
JAK2, IC50: 18 nM
JAK3, IC50: 155 nM
    98.93%
WP1066  
JAK2
      99.90%
Filgotinib
JAK1, IC50: 10 nM
JAK2, IC50: 28 nM
JAK3, IC50: 810 nM
Tyk2, IC50: 116 nM
  99.37%
Peficitinib
JAK1, IC50: 3.9 nM
JAK2, IC50: 5 nM
JAK3, IC50: 0.7 nM
Tyk2, IC50: 4.8 nM
  99.43%
Ritlecitinib    
JAK3, IC50: 33.1 nM
    99.98%
(E/Z)-Zotiraciclib  
JAK2, IC50: 73 nM
      99.96%
Itacitinib
JAK1
        99.97%
AZD-1480
JAK1, IC50: 1.3 nM
JAK2, IC50: <0.4 nM
      99.37%
AT9283  
JAK2, IC50: 1.2 nM
JAK3, IC50: 1.1 nM
    99.70%
Fedratinib hydrochloride hydrate  
JAK2, IC50: 3 nM
JAK2(V617F), IC50: 3 nM
      99.86%
Abrocitinib
JAK1, IC50: 29 nM
JAK2, IC50: 803 nM
 
Tyk2, IC50: 1253 nM
  99.26%
Gandotinib  
JAK2, IC50: 3 nM
JAK3, IC50: 48 nM
Tyk2, IC50: 44 nM
  99.82%
Cucurbitacin I  
JAK2
      ≥98.0%
CHZ868  
JAK2, IC50: 110 nM
      99.38%
RO8191
JAK1
        ≥99.0%
Delgocitinib
JAK1, IC50: 2.8 nM
JAK2, IC50: 2.6 nM
JAK3, IC50: 13 nM
Tyk2, IC50: 58 nM
  99.76%
Pyridone 6
Murine JAK1, IC50: 15 nM
JAK2, IC50: 1 nM
JAK3, IC50: 5 nM
Tyk2, IC50: 1 nM
  98.84%
Cerdulatinib
JAK1, IC50: 12 nM
JAK2, IC50: 6 nM
JAK3, IC50: 8 nM
Tyk2, IC50: 0.5 nM
  99.0%
TG101209  
JAK2, IC50: 6 nM
JAK3, IC50: 169 nM
    99.22%
Baricitinib phosphate
JAK1, IC50: 5.9 nM
JAK2, IC50: 5.7 nM
JAK3, IC50: 560 nM
Tyk2, IC50: 53 nM
  99.91%
Brepocitinib P-Tosylate
JAK1, IC50: 17 nM
JAK2, IC50: 77 nM
JAK3, IC50: 6.9 μM
    99.69%
Oclacitinib maleate
JAK1, IC50: 10 nM
JAK2, IC50: 18 nM
JAK3, IC50: 99 nM
Tyk2, IC50: 84 nM
  99.65%
XL019  
JAK2, IC50: 2.2 nM
JAK3, IC50: 214.2 nM
    ≥98.0%
JANEX-1    
JAK3, IC50: 78 μM
    99.60%
Ilginatinib
JAK1, IC50: 33 nM
JAK2, IC50: 0.72 nM
JAK3, IC50: 39 nM
Tyk2, IC50: 22 nM
  99.53%
Decernotinib
JAK1, Ki: 11 nM
JAK2, Ki: 13 nM
JAK3, Ki: 2.5 nM
Tyk2, Ki: 11 nM
  99.67%
BMS-986202      
Tyk2 JH2, IC50: 0.19 nM
Tyk2 JH2, Ki: 0.02 nM
  99.46%
Lestaurtinib  
JAK2, IC50: 0.9 nM
      99.92%
BMS-911543
JAK1, IC50: 75 nM
JAK2, IC50: 1.1 nM
JAK3, IC50: 360 nM
Tyk2, IC50: 66 nM
  98.53%
RGB-286638  
JAK2, IC50: 50 nM
      99.84%
Tyk2-IN-5      
Tyk2 JH2, Ki: 0.086 nM
  98.87%
CEP-33779  
JAK2, IC50: 1.8 nM
JAK3, IC50: 150 nM
    99.36%
AZ960  
JAK2, Ki: 0.45 nM
JAK2, IC50: <3 nM
JAK3, IC50: 9 nM
   
Ruxolitinib (S enantiomer)        
JAK
99.77%
Golidocitinib
JAK1, IC50: 73 nM
        99.75%
Cerdulatinib hydrochloride
JAK1, IC50: 12 nM
JAK2, IC50: 6 nM
JAK3, IC50: 8 nM
Tyk2, IC50: 0.5 nM
  99.54%
WHI-P154    
JAK3, IC50: 1.8 μM
    99.39%
TyK2-IN-2      
Tyk2 JH2, IC50: 7 nM
  99.71%
FM-381    
JAK3, IC50: 127 pM
    98.25%
Solcitinib
JAK1, IC50: 9.8 nM
        99.73%
SAR-20347
JAK1, IC50: 23 nM
JAK2, IC50: 26 nM
JAK3, IC50: 41 nM
Tyk2, IC50: 0.6 nM
 
ZM39923 hydrochloride
JAK1, pIC50: 4.4
 
JAK3, pIC50: 7.1
    99.86%
SC99  
JAK2
      99.07%
JAK/HDAC-IN-1
JAK1, IC50: 4.8 nM
JAK2, IC50: 4 nM
JAK3, IC50: 7.4 nM
Tyk2, IC50: 49 nM
  98.53%
Momelotinib sulfate
JAK1, IC50: 11 nM
JAK2, IC50: 18 nM
JAK3, IC50: 155 nM
    98.04%
NSC 42834  
JAK2-WT, IC50: 15 μM
JAK2-V617F, IC50: 28 μM
      98.01%
Ivarmacitinib
JAK1
JAK2
JAK3
Tyk2
  99.58%
BD750    
JAK3
    99.79%
TCS 21311
JAK1, IC50: 1.017 μM
JAK2, IC50: 2.55 μM
JAK3, IC50: 8 nM
    99.18%
NVP-BSK805 dihydrochloride
JAK1 JH1, IC50: 31.63 nM
JAK2 JH1, IC50: 0.48 nM
FL JAK2 V617F, IC50: 0.56 nM
FL JAK2 wt, IC50: 0.58 nM
JAK3 JH1, IC50: 18.68 nM
TYK2 JH1, IC50: 10.76 nM
  99.81%
WHI-P97    
JAK3, IC50: 11 μM
    99.13%
Ilginatinib hydrochloride
JAK1, IC50: 33 nM
JAK2, IC50: 0.72 nM
JAK3, IC50: 39 nM
Tyk2, IC50: 22 nM
  ≥98.0%
Itacnosertib  
JAK2
      99.77%
JAK3-IN-6    
JAK3, IC50: 0.15 nM
    98.07%
GLPG0634 analog
JAK1, IC50: <100 nM
JAK2, IC50: <100 nM
JAK3, IC50: <100 nM
Tyk2, IC50: <100 nM
  98.58%
PF-06263276
JAK1, IC50: 2.2 nM
JAK2, IC50: 23.1 nM
JAK3, IC50: 59.9 nM
Tyk2, IC50: 29.7 nM
  ≥99.0%
Tyk2-IN-7      
Tyk2 JH2, IC50: 0.00053 μM
Tyk2 JH2, Ki app: 0.00007 μM
  99.66%
Itacitinib adipate
JAK1
        99.18%
SJ10542  
JAK2, DC50: 14 nM
JAK3, DC50: 11 nM
    99.92%
Reticuline  
JAK2
      98.91%
G5-7  
JAK2
      99.84%
Protosappanin A  
JAK2
      99.98%
2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
JAK1, Ki: 0.7 nM
JAK2, Ki: 0.7 nM
JAK3, Ki: 0.4 nM
Tyk2, Ki: 4.8 nM
  98.78%
RGB-286638 free base  
JAK2, IC50: 50 nM
      98.07%
Ilginatinib maleate
JAK1, IC50: 33 nM
JAK2, IC50: 0.72 nM
JAK3, IC50: 39 nM
Tyk2, IC50: 22 nM
 
NVP-BSK805
JAK1 JH1, IC50: 31.63 nM
JAK2 JH1, IC50: 0.48 nM
FL JAK2 V617F, IC50: 0.56 nM
FL JAK2 wt, IC50: 0.58 nM
JAK3 JH1, IC50: 18.68 nM
TYK2 JH1, IC50: 10.76 nM
  99.76%
JAK2-IN-7
JAK1, IC50: 42 nM
JAK2, IC50: 3 nM
JAK3, IC50: 94 nM
Tyk2, IC50: 75 nM
  99.42%
JAK2/FLT3-IN-1 TFA
JAK1, IC50: 26 nM
JAK2, IC50: 0.7 nM
JAK3, IC50: 39 nM
   
JAK3-IN-1
JAK1, IC50: 896 nM
JAK2, IC50: 1050 nM
JAK3, IC50: 4.8 nM
    99.23%
(2R,5S)-Ritlecitinib    
JAK3, IC50: 144.8 nM
    98.83%
(E/Z)-Zotiraciclib hydrochloride  
JAK2
      99.45%
JAK1-IN-8
JAK1, IC50: <500 nM
JAK2, IC50: 500-1000 nM
JAK3, IC50: >5000 nM
   
GSK2646264  
JAK2, pIC50: 5
      98.39%
Brepocitinib
JAK1, IC50: 17 nM
JAK2, IC50: 77 nM
JAK3, IC50: 6.9 μM
   
(E/Z)-Zotiraciclib citrate  
JAK2
      98.06%
JAK2-IN-6  
JAK2, IC50: 22.86 μg/mL
     
JAK-IN-23
JAK1, IC50: 8.9 nM
JAK2, IC50: 15 nM
JAK3, IC50: 46.2 nM
   
Upadacitinib tartrate tetrahydrate
JAK1, IC50: 0.043 μM
JAK2, IC50: 0.2 μM
JAK3, IC50: 2.3 μM
Tyk2, IC50: 4.7 μM
 
Peficitinib hydrobromide
JAK1, IC50: 3.9 nM
JAK2, IC50: 5 nM
JAK3, IC50: 0.7 nM
Tyk2, IC50: 4.8 nM
 
NVP-BSK805 trihydrochloride
JAK1 JH1, IC50: 31.68 nM
JAK2 JH1, IC50: 0.48 nM
JAK2(V617F), IC50: 0.56 nM
FL JAK2 wt, IC50: 0.58 nM
 
TYK2 JH1, IC50: 18.68 nM
 
JAK1-IN-4
JAK1, IC50: 85 nM
JAK2, IC50: 12.8 μM
     
JAK2/FLT3-IN-1
JAK1, IC50: 26 nM
JAK2, IC50: 0.7 nM
JAK3, IC50: 39 nM
   
AZD4604
JAK1
       
JAK-IN-4        
JAK
Nezulcitinib        
JAK
JAK-IN-3
JAK1, IC50: 5 nM
JAK2, IC50: 70 nM
JAK3, IC50: 3 nM
Tyk2, IC50: 34 nM
 
Filgotinib maleate
JAK1, IC50: 10 nM
JAK2, IC50: 28 nM
JAK3, IC50: 810 nM
Tyk2, IC50: 116 nM
 
Pacritinib hydrochloride
JAK1, IC50: 1280 nM
JAK2V617F, IC50: 19 nM
JAK2wt, IC50: 23 nM
JAK3, IC50: 520 nM
Tyk2, IC50: 50 nM
 
TUL01101
JAK1, IC50: 3 nM
JAK2, IC50: 37 nM
JAK3, IC50: 1517 nM
Tyk2, IC50: 36 nM
 
Deuruxolitinib
JAK1
JAK2
     
JAK3 covalent inhibitor-1    
JAK3, IC50: 11 nM
   
Tyk2-IN-3      
Tyk2, IC50: 485 nM
 
Momelotinib-d2
JAK1, IC50: 11 nM
JAK2, IC50: 18 nM
     
JAK-2/3-IN-3  
JAK2, IC50: 13.00 nM
JAK3, IC50: 14.86 nM
   
JAK-2/3-IN-1  
JAK2, Ki: <250 nM
JAK3, Ki: <250 nM
   
BMS-066      
Tyk2, IC50: 72 nM
 
Peficitinib hydrochloride
JAK1, IC50: 3.9 nM
JAK2, IC50: 5 nM
JAK3, IC50: 0.7 nM
Tyk2, IC50: 4.8 nM
 
Ten01
JAK1, IC50: 5 nM
       
SD-1029  
JAK2
     
Thi-DPPY    
JAK3, IC50: 1.38 nM
   
JAK1/TYK2-IN-3
JAK1, IC50: 37 nM
JAK2, IC50: 140 nM
JAK3, IC50: 362 nM
Tyk2, IC50: 6 nM
 
PF-00956980
JAK1, IC50: 2.2 μM
JAK2, IC50: 23.1 μM
JAK3, IC50: 59.9 μM
   
Momelotinib-2,2,6,6-d4
JAK1, IC50: 11 nM
JAK2, IC50: 18 nM
     
TK4b  
JAK2, IC50: 19.40 nM
JAK3, IC50: 18.42 nM
   
JAK3-IN-9    
JAK3, IC50: 1.7 nM
   
Momelotinib-d10
JAK1, IC50: 11 nM
JAK2, IC50: 18 nM
     
SJ988497  
JAK2
     
JAK2 JH2 binder-1  
JAK2 JH2, Kd: 37.1 nM
     
JAK3-IN-11
JAK1, IC50: 1.32 μM
JAK2, IC50: 1 μM
JAK3, IC50: 1.7 nM
   
JAK-2/3-IN-2  
JAK2, IC50: 23.85 nM
JAK3, IC50: 18.9 nM
   
DPPY    
JAK3, IC50: <10 nM
   
JAK1-IN-9
JAK1, IC50: 72 nM
JAK2, IC50: 839 nM
     
JAK-IN-21
JAK1, IC50: 1.73 nM
JAK2, IC50: 2.04 nM
JAK2-V617F, IC50: 109 nM
 
Tyk2, IC50: 62.9 nM
 
Momelotinib-d8
JAK1, IC50: 11 nM
JAK2, IC50: 18 nM
     
MS-1020    
JAK3
   
NSC 33994  
JAK2, IC50: 60 nM (JAK2 Val617Phe kinase activity )
     
JI6    
JAK3, IC50: ~250 nM
   
Broussonin E  
JAK2
     
FM-479    
JAK3
   
JAK3/BTK-IN-6
JAK1, IC50: >1000 nM
JAK2, IC50: 657.9 nM
JAK3, IC50: 0.4 nM
Tyk2, IC50: >1000 nM
 
ZT55  
JAK2, IC50: 0.031 μM
     
TK4g  
JAK2, IC50: 12.61 nM
JAK3, IC50: 15.80 nM
   
JAK2/TYK2-IN-1  
JAK2, IC50: 157 nM
 
Tyk2, IC50: 9 nM
 
TYK2-IN-12
JAK1, Ki: 45.9 nM
JAK2, Ki: 21.93 nM
JAK3, Ki: 6.63 nM
Tyk2, Ki: 0.51 nM
 
HG-7-85-01
JAK1, IC50: 120 nM
       
TCJL37      
Tyk2, Ki: 1.6 nM
 
JAK3-IN-12
JAK1, IC50: 18 nM
JAK2, IC50: 42 nM
JAK3, IC50: 9.5 nM
   
JAK-IN-20
JAK1, IC50: 7 nM
JAK2, IC50: 5 nM
JAK3, IC50: 14 nM
   
Ruxolitinib sulfate
JAK1, IC50: 3.3 nM
JAK2, IC50: 2.8 nM
JAK3, IC50: 428 nM
Tyk2, IC50: 19 nM
 
Momelotinib Mesylate
JAK1, IC50: 11 nM
JAK2, IC50: 18 nM
JAK3, IC50: 155 nM
   
SD-1008  
JAK2
     
ZM39923
JAK1, pIC50: 4.4
 
JAK3, pIC50: 7.1
   
JAK-IN-11        
JAK
JAK3-IN-7    
JAK3, IC50: 0.01 μM
   
JAK-IN-10        
JAK